December 5, 2025Frontiers in Nuclear Medicine11 citationsOpen Access

Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors

YWYu WangBGI Group (China)YLYingchun LiShenzhen University WHWenli HuHainan Normal University

Key Points

Current clinical landscape highlights the potential of fibroblast activation protein as a therapeutic target for solid tumors.
FAP, prevalent in over 90% of epithelial malignancies, drives interest in innovative radioligand therapy approaches.
Observations include the implementation of positron emission tomography for FAP as a novel imaging method.
Challenges persist in merging clinical practice with emerging technologies in radioligand therapy.

Abstract

Fibroblast activation protein (FAP) is a type II transmembrane serine protease predominantly expressed by cancer-associated fibroblasts (CAFs) in more than 90% of epithelial malignancies. The advent of FAP inhibitor (FAPI)-based positron emission tomography (PET) imaging has established FAP as a promising pan-tumor target for radioligand therapy (RLT). This review summarizes the current clinical landscape of FAP-targeted RLT in solid tumors, while also discussing existing challenges and future directions in this rapidly evolving field.

Ask AI

Helpful

Bookmark

View Full Paper